Yuyu Pharma's Dry Eye Treatment 'YP-P10' Receives FDA Approval for Phase 2 Clinical Trial in the US

by Lee Gwanju

Published 12 Apr.2022 09:17(KST)

Exterior view of Yuyu Pharmaceutical Jecheon Plant.

[Asia Economy Reporter Lee Gwan-joo] Yuyu Pharma announced on the 12th that its dry eye syndrome treatment 'YP-P10' has received approval from the U.S. Food and Drug Administration (FDA) for its Phase 2 clinical trial.

YP-P10 is a biopharmaceutical using synthetic peptides designed to treat dry eye syndrome by being administered twice daily, aiming to alleviate signs and symptoms of dry eye caused by inflammation. Animal studies have confirmed that it has superior anti-inflammatory mechanisms and excellent corneal epithelial cell healing effects compared to existing drugs.

Yoo Won-sang, CEO of Yuyu Pharma, stated, “We have received final confirmation from the U.S. FDA to proceed with the Phase 2 clinical trial of YP-P10, and we plan to administer the first dose to patients within the first half of the year.”

Yuyu Pharma is focusing on three new drug pipelines including YP-P10, a combination drug for benign prostatic hyperplasia, and a multiple sclerosis treatment being jointly researched with UCLA. They are also developing new drug candidates for hair loss and stroke recovery.